

ASX Announcement

29 February 2024

BCAL STRENGTHENS BOARD WITH COMMERCIAL NED

Breast cancer screening and diagnostic company BCAL Diagnostics Limited (ASX:BDX, 'BCAL' or the 'Company') is pleased to announce the appointment of Mr David Darling as a Non-Executive Director with effect from 1 March 2024. Mr Darling will replace Dr Merilyn Sleigh who will retire from the Board on 29 February 2024.

David Darling is a highly credentialed leader and executive who brings a wealth of commercial experience to BCAL from his prior role as CEO of Pacific Edge, a NZX50 and ASX listed business focused on commercialising its bladder cancer diagnostics tests across global markets, with commercial operations in New Zealand, Australia, Singapore and the USA. Prior to Pacific Edge, Mr Darling held senior management positions with Fletcher Challenge.

Mr Darling has a background as a scientist with a specialty in genetics and has more than three decades of experience in developing and commercialising life sciences and biotechnology products which will be an asset to BCAL as it reaches an inflection point in the commercialisation of its proprietary non-invasive breast cancer diagnostic blood test BREASTEST™.

Mr Darling has dedicated his career to building and growing companies across the life sciences and biotechnology sectors where he focused on the growth and international commercialisation of these start-up and young companies. Mr Darling also brings a wealth of governance and executive management experience having served as a director of Pacific Edge and its subsidiary businesses in New Zealand, Australia, Singapore and the USA. He is also is a board director on a number of private business and organisation boards.

BCAL Diagnostics Chair, Jayne Shaw said *"We are delighted to welcome David to the BCAL Board of Directors where his commercial acumen and strategic growth experience will be invaluable as we rapidly progress towards the commercial launch of BREASTEST™. At this inflection point we have prioritised strengthening our Board with commercial expertise and we are confident David will have an immediate impact."*

On behalf of the Board our sincere thanks to Dr Merilyn Sleigh for her outstanding contribution to BCAL over the past 3 years since joining the Board in March 2021 shortly before the ASX listing."

This announcement has been approved for release by the Board.

ENDS**For further information:****Jayne Shaw**

Executive Chair

Jshaw@bcaldiagnostics.com

Guy Robertson

Chief Financial Officer

grobertson@bcaldiagnostics.com

About BCAL Diagnostics

BCAL Diagnostics Limited is an Australian screening and diagnostic company committed to the early, accurate diagnosis of breast cancer, and therefore early intervention and improved outcomes for women. Over the past decade BCAL has developed a non-invasive blood test for the detection of breast cancer, with results to date demonstrating 90% sensitivity and 85.5% specificity. The test is initially designed to complement current imaging technologies, such as the mammogram, with the aim of becoming a monitoring and screening tool suitable for women of all ages and backgrounds in any location. With more than two million new cases of breast cancer diagnosed globally each year, a substantial opportunity exists for BCAL to improve patient outcomes.

Founded in 2010, BCAL is headquartered in Sydney and listed on the Australian Securities Exchange (ASX: BDX). For more information: <https://www.bcaldiagnostics.com/>